Antibacterial Nanoparticles Therapeutic ( ANT ) Study

2026-11-03

The BDB seeks to conduct a study to test innovative antibacterial nanoparticles with phage - mimicking properties ( PhANPs ) against combat relevant multi - drug resistant ( MDR ) strains of Pseudomonas ( P .) aeruginosa , bacterial pathogen to cause hard to treat and even deadly infections in service members after battlefield injuries . There is a need to bring novel therapeutics to the military health care to treat MDR P . aeruginosa . The collaborative partner of this study is the University of Notre Dame , the patent owner of a unique technology ( phage - mimicking nanoparticles ) that provides life - saving therapeutics for service members and civilians . This technology was awarded a patent in 2024 - US - 12161725 - B2 . Government anticipates that the collaborative efforts will contribute to Food and Drug Administration ( FDA ) approval of this innovative therapy , leading to reduced morbidity and mortality rates , enhanced operational readiness , advanced combat medicine , and substantial contributions to broader biosecurity initiatives and civilian health improvements . The contractor shall provide non - personal Research and Development effort . This includes qualified research personnel , appropriate laboratory facilities , and all necessary laboratory and research related materials and supplies .

Maryland

2026-04-08